Otros idiomas Satellos Bioscience Inc.

Acciones

MSCL

CA80401L3083

Mercado cerrado - Toronto S.E. Otros sitios de cotización 21:59:59 16/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,48 ^CAD	+2,13 %		+6,67 %	+11,63 %

14/05	Aumentan las pérdidas de Satellos Bioscience en el primer trimestre debido al incremento de los gastos; pero afirma estar "en camino" de iniciar los ensayos clínicos de fase 1 en humanos a mediados de 2024	MT
27/03	Satellos Bioscience Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Satellos Bioscience Inc. Opens the Market	15/05
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders	14/05
Satellos Bioscience: Q1 Earnings Snapshot	14/05
Satellos Bioscience Q1 Loss Widens Due To Higher Expenses; But Says "On track" to initiate Phase 1 First-in-human Clinical Trials Mid-2024	14/05
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights	14/05
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	08/04
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Satellos Bioscience: Q4 Earnings Snapshot	27/03
Satellos Bioscience Announces FY 2023 Results	27/03
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights	27/03
Satellos to Present at Upcoming Virtual Investor Conferences in March and April	14/03
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024	05/03
Satellos Presented "Positive" Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04/03
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04/03
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	04/03
Satellos Recognized as a Top 50 TSX Venture Exchange Company	21/02
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference	20/02
Satellos Bioscience Inc. Brief: Says Will commence trading on the Toronto Stock Exchange as of the opening of trading tomorrow	14/02
Satellos to Commence Trading on the Toronto Stock Exchange	14/02
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	13/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Satellos Bioscience Inc.

Acciones

MSCL

CA80401L3083

Otros idiomas

Filtros